Navigation Links
Switzerland signs the ELIXIR consortium agreement and contributes €35 million
Date:10/30/2013

Switzerland's State Secretary for Education, Research and Innovation, Dr Mauro Dell'Ambrogio, has signed the ELIXIR Consortium Agreement for the establishment of ELIXIR, the European Life science Infrastructure for Biological Information. This brings closer the time when five Member States will have signed, and the Consortium Agreement will enter into force. The Swiss government has committed to investing 35 million over the four-year period from 2013 to 2016. This monetary contribution is mainly provided through financial support to SIB Swiss Institute of Bioinformatics the Swiss ELIXIR Node. However, the experience and expertise of SIB are also an important part of Switzerland's participation. Access to SIB's bioinformatics core resources and many other high-quality services, as well as the benefit of its solid experience in bioinformatics training will be major assets in the launch and success of ELIXIR.

The deluge of data produced by life science researchers thanks to new-generation technologies is a very positive development, given the wealth of information hidden in this data. Our society is constantly being challenged by crucial questions related to food, energy, the environment and, of course, health. Such data is a windfall for researchers provided that both the information and the bioinformatics resources for its analysis are accessible over the long term. ELIXIR is the European consortium, whose aim is to set up and operate a sustainable European infrastructure for biological information to support life science research and its translation to medicine, the environment, the bio-industries and society. This requires international coordination and the assurance of long-term funding.

The International Consortium Agreement signed by Switzerland today is key for the set-up of ELIXIR. Niklas Blomberg, Director of ELIXIR, is "very pleased that Switzerland, a pioneer and one of the world leaders in bioinformatics, is one of the first Member States to ratify the Agreement". Switzerland, which had already signed the Memorandum of Understanding in 2011, has thus confirmed its participation in the project. Research, life sciences and bioinformatics have been strongly supported by the Swiss government for many years, which is one of the reasons why Switzerland currently has a robust bioinformatics infrastructure.

SIB, the Swiss node of ELIXIR, is pleased to lend its support to ELIXIR

Since its inception, SIB, which is celebrating its 15th anniversary this year, has positioned itself as a major contributor to the life sciences. UniProtKB/Swiss-Prot, neXtProt, STRING, SWISS-MODEL are only a few of the core resources that have been created by SIB and are available to the life science research community worldwide. In total, more than 130 resources are accessible through SIB's web portal ExPASy (http://www.expasy.org). SIB, whose infrastructure and research groups are located in the major Swiss Universities and Federal Institutes of Technology, has a long experience in interinstitutional, intercantonal and international collaboration. Training the next generation of bioinformaticians is another of the Institute's roles, and demonstrates how SIB's missions are in tune with those of ELIXIR. According to Ron Appel, Executive Director of SIB, "ELIXIR will give a new dimension to European collaboration and open the door to the future of science".


'/>"/>

Contact: Irene Perovsek
irene.perovsek@isb-sib.ch
41-216-924-054
Swiss Institute of Bioinformatics
Source:Eurekalert

Related biology news :

1. Empa researchers join Quantis to open new branch in Switzerland
2. BioClaim, Inc. Signs Biometric Software Contract with Amerigroup Florida
3. Leopoldina signs cooperation agreement with the Academy of Science of South Africa
4. Fluke Biomedical launches portable, feature-rich ProSim 3 and 2 Vital Signs Simulators
5. Light and nanoprobes detect early signs of infection
6. Encouraging signs for bee biodiversity
7. Early warning signs of population collapse
8. Shedding light on a gene mutation that causes signs of premature aging
9. Genetic signs of alcoholism in women studied for the first time
10. Streams show signs of degradation at earliest stages of urban development
11. Wiley signs collaboration agreement with the Asian Federation of Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... --  EyeLock LLC , a market leader of iris-based ... IoT Center of Excellence in Austin, Texas ... embedded iris biometric applications. EyeLock,s iris authentication ... with unmatched biometric accuracy, making it the most proven ... platform uses video technology to deliver a fast and ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: